Chronic hepatitis B
Conditions
Interventions
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age of 18-65 years old, male and female (including 18 and 65 years old); (2) For patients with chronic HBV infection, the inclusion criteria referred to the Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition). (3) A negative urine or serum pregnancy test within 24 hours before the first dose (for women of reproductive age); (4) Patients actively cooperated with good compliance, were willing to accept treatment and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Other causes of liver injury, such as cirrhosis, other viral hepatitis, alcoholic hepatitis, autoimmune liver injury, drug-induced liver injury, etc. (2) Patients with HIV infection or other immunodeficiency diseases; (3) Psychiatric history (schizophrenia or major depression), uncontrolled epilepsy, decompensated liver cirrhosis, or uncontrolled autoimmune disease; (4) Severe infection, retinal disease, heart failure, chronic obstructive pulmonary disease and other basic diseases; (5) Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs; (6) Patients with other serious complications (such as severe infection, gastrointestinal bleeding, hepatorenal syndrome); (7) Relative contraindications: thyroid disease, previous history of depression, uncontrolled diabetes, heart disease; (8) Patients who are allergic to interferon and its drug components, allergic to aspirin and its drug components, and who are not suitable for interferon and aspirin according to the investigator's judgment; (9) Decompensated cirrhosis, or patients with a history of decompensated cirrhosis; (10) ALT > 10 times upper limit of normal, total bilirubin > 2 times upper limit of normal; (11) Lower than the lower limit of normal in peripheral white blood cell count and/or platelet count; (12) Patients with confirmed or suspected liver cancer or other malignant tumors; (13) After or preparing for organ transplantation; (14) Patients using immunosuppressants; (15) Pregnant or planning to become pregnant within 2 years; (16) Unable to comply with the study arrangements and sign the informed consent; (17) Other conditions judged by the investigator to be ineligible for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;HBsAg. HbsAb. HbeAg. HbeAb. HbcAb;ALT. AST; | — |
Countries
China
Contacts
Public ContactHui Zheng, Liangping Li, Yuming Luo
Sichuan Provincial People's Hospital
Outcome results
None listed